CPIX, Cumberland Pharmaceuticals Inc.
** CPIX reported that it has entered into an exclusive agreement with China's Harbin Gloria Pharmaceuticals Co., Ltd. for the commercialization of Acetadote (acetylcysteine), its injectable drug used to treat acetaminophen overdose, and Caldolor (ibuprofen) Injection, which is used to treat pain and fever in the hospital setting. The agreement will provide Harbin Gloria exclusive rights to register and commercialize both drugs in China.
Under the terms of the agreement, Harbin Gloria is responsible for seeking regulatory approval for the two injectable products in China, and would handle ongoing regulatory reporting, product marketing, distribution and sales in the territory following approval. CPIX maintains responsibility for the intellectual property, product formulation, development and other supporting activities.
According to the company, in exchange for the license to the product, CPIX will receive upfront and milestone licensing payments, as well as royalties on future sales of both drugs.
While CPIX focuses its proprietary commercial efforts on the United States, CPIX has significantly expanded its international network of partners in recent years. In addition to its arrangement with Harbin Gloria, CPIX has licensed rights for Caldolor to partners in South Korea, Malaysia, Dubai, Canada, Australia and New Zealand.
Following regulatory approval, Harbin Gloria will use its existing sales force to promote these injectable products throughout China. Both offer unique benefits not currently available to hospitalized patients in China. In the U.S., Acetadote is used in emergency departments to prevent or lessen potential liver damage resulting from an overdose of acetaminophen, a common ingredient in many over-the-counter pain relief and fever reducing products. Acetadote has become a standard of care for treating acetaminophen poisoning in the U.S. since its introduction in 2004.
Harbin Gloria is expected to introduce the first injectable ibuprofen product in China. It features analgesic, antipyretic and anti-inflammatory properties and is designed for the treatment of pain and fever, primarily in hospitalized patients who are unable to receive oral therapies. In clinical trials, Caldolor has demonstrated significant reductions in post-operative pain when compared with opioids alone while significantly reducing opioid requirements.
CPIX is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. CPIX's primary target markets include hospital acute care and gastroenterology.
More about CPIX at www.cumberlandpharma.com.
EXLS, ExlService Holdings Inc.
** In the fourth quarter 2011, EXLS achieved record revenues of $102.6 million, a 46.5% increase compared to $70.0 million in the same period the prior year.
For 2012, EXLS is providing revenue guidance of $445.0 million to $455.0 million, representing annual revenue growth of 24% to 27%, excluding revenues from a one-time client payment received in 2011. For 2012, based on current exchange rates, EXLS expects to achieve adjusted diluted earnings per share of $1.50 to $1.55.
EXLS is a leading provider of outsourcing and transformation services. EXLS primarily serves the needs of Global 1000 companies from global delivery centers in the insurance, utilities, banking and financial services, transportation and logistics, and travel sectors.
More about EXLS at www.exlservice.com.
EXE, Crexendo Inc.
** For the fourth quarter of 2011, EXE posted net income of $459,000 or $0.03 per diluted common share, compared to a net loss of $2,405,000 or $0.21 per diluted common share in the same period the prior year.
Cash from operations for the fourth quarter of 2011 was $1,441,000 compared to $665,000 for the prior year quarter.
EXE provides Cloud-based infrastructure services to businesses, which includes telecom and website hosting services, ecommerce software, website development and Internet marketing services.
More about EXE at www.crexendo.com.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyOmega.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyOmega.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://pennyomega.com/disclaimer). Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.